Hemab Therapeutics Holdings, Inc. (COAG) shareholders
Close on Nov 17, 2026Market cap $1.82BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Rajeev Shah Joint filing with RA Capital Management, L.P. (16.60%), Peter Kolchinsky (16.60%) and 1 more | 7,729,773 | 16.60% | 13G (passive) | May 4, 2026 |
| Access Industries Holdings LLC Joint filing with Ai Den-Mab LLC (10.40%), AI Biotechnology LLC (10.40%) and 2 more | 4,876,344 | 10.40% | 13D (active) | May 4, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (10.40%) | 4,871,850 | 10.40% | 13G (passive) amendment | Oct 30, 2026 |
| Novo Holdings A/S | 4,180,550 | 9.00% | 13G (passive) | Jun 30, 2026 |
| Capital International Investors | 3,603,876 | 7.70% | 13G (passive) | Jun 30, 2026 |
| David Kroin Joint filing with Deep Track Capital, LP (8.15%), Deep Track Biotechnology Master Fund, Ltd. (6.75%) | 3,600,996 | 8.15% | 13G (passive) | May 1, 2026 |
| Behzad Aghazadeh | 3,298,236 | 7.06% | 13G (passive) | Jun 30, 2026 |
| Joseph Anderson Joint filing with Sofinnova Crossover II SLP (5.40%), Sofinnova Partners SAS, a French corporation (5.40%) and 4 more | 2,511,212 | 5.40% | 13G (passive) | Jun 30, 2026 |
| Raymond Debbane | 2,366,235 | 5.10% | 13G (passive) | Aug 3, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of COAG | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 7,808,627 | 16.72% | $286.81M | New | 2.49% |
| Novo Holdings A/S | 4,180,550 | 8.95% | $153.55M | New | 8.92% |
| FMR LLC | 3,697,837 | 7.92% | $135.82M | New | 0.01% |
| Capital International Investors | 3,603,876 | 7.72% | $132.37M | New | 0.03% |
| Deep Track Capital, LP | 3,602,093 | 7.71% | $132.30M | New | 1.93% |
| Siren, L.L.C. | 2,086,834 | 4.47% | $76.65M | New | 1.55% |
| Avoro Capital Advisors LLC | 1,925,150 | 4.12% | $70.71M | New | 0.63% |
| Bain Capital Life Sciences Investors, LLC | 1,650,000 | 3.53% | $60.60M | New | 3.60% |
| JPMorgan Chase & Co | 1,152,420 | 2.47% | $42.33M | New | 0.00% |
| Vanguard Capital Management LLC | 780,758 | 1.67% | $28.68M | New | 0.00% |
| Price T Rowe Associates Inc /Md/ | 746,040 | 1.60% | $27.40M | New | 0.00% |
| Driehaus Capital Management LLC | 715,791 | 1.53% | $26.29M | New | 0.15% |
| Rock Springs Capital Management LP | 575,432 | 1.23% | $21.14M | New | 1.03% |
| Bellevue Group AG | 550,000 | 1.18% | $20.20M | New | 0.43% |
| Citadel Advisors LLC | 523,450 | 1.12% | $19.23M | New | 0.00% |
| BlackRock, Inc. | 283,833 | 0.61% | $10.43M | New | 0.00% |
| Deerfield Management Company, L.P. (Series C) | 275,000 | 0.59% | $10.10M | New | 0.11% |
| ExodusPoint Capital Management, LP | 218,287 | 0.47% | $8.02M | New | 0.05% |
| Geode Capital Management, LLC | 211,798 | 0.45% | $7.78M | New | 0.00% |
| Braidwell LP | 160,000 | 0.34% | $5.88M | New | 0.22% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 55 | 36M | 77.5% | 55 / 0 | 0 / 0 | 36M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of COAG | Value | % of fund | As of |
|---|---|---|---|---|---|
| SMALLCAP World Fund Inc | 2,157,914 | 4.62% | $79.26M | 0.08% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 1,348,629 | 2.89% | $49.54M | 0.05% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 555,543 | 1.19% | $20.41M | 0.00% | Jun 30, 2026 |
| JPMorgan Small Cap Growth Fund | 531,382 | 1.14% | $19.52M | 0.75% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 524,500 | 1.12% | $14.95M | 0.02% | May 31, 2026 |
| Fidelity Stock Selector Small Cap Fund | 439,953 | 0.94% | $20.92M | 0.28% | Jul 31, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 412,400 | 0.88% | $11.75M | 0.00% | May 31, 2026 |
| Select Biotechnology Portfolio | 379,476 | 0.81% | $10.82M | 0.21% | May 31, 2026 |
| Fidelity Series Small Cap Opportunities Fund | 267,754 | 0.57% | $12.73M | 0.27% | Jul 31, 2026 |
| Fidelity Blue Chip Growth Fund | 236,200 | 0.51% | $11.23M | 0.01% | Jul 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 206,840 | 0.44% | $7.60M | 0.06% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 203,551 | 0.44% | $7.48M | 0.01% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 186,700 | 0.40% | $8.88M | 0.40% | Jul 31, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 174,541 | 0.37% | $6.41M | 0.04% | Jun 30, 2026 |
| JPMorgan Small Cap Blend Fund | 171,281 | 0.37% | $6.29M | 0.37% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Benny Sorensen | See Remarks, Director | – | – | Apr 30, 2026 |
| Catherine Madigan | Chief Medical Officer | – | – | May 4, 2026 |
| Mads Nikolaj Behrndt-Eriksen | See Remarks | 36,520 | 0.08% | May 4, 2026 |
| Ananthram Sreenivasa Murthy | Chief Operating Officer | – | – | Apr 30, 2026 |
| Keli Walbert | Director | – | – | Sep 25, 2026 |
| RA Capital Nexus Fund IV, L.P. | Director | – | – | May 6, 2026 |
| RA Capital Nexus Fund II, L.P. | Director | – | – | May 6, 2026 |
| John Maraganore | Director | 17,974 | 0.04% | May 4, 2026 |
| Linda Bain | Director | – | – | Apr 30, 2026 |
| Laura Tadvalkar | Director | – | – | Apr 30, 2026 |
| Akshay Vaishnaw | Director | – | – | Apr 30, 2026 |
| Ra Capital Management, L.P. | 10% owner | 6,444,637 | 13.80% | Jun 17, 2026 |
| Capital Healthcare Fund LP RA | 10% owner | 6,340,063 | 13.57% | Jun 17, 2026 |
| Peter Kolchinsky | 10% owner | 6,372,170 | 13.64% | Jun 17, 2026 |
| Rajeev M. Shah | 10% owner | 6,261,118 | 13.40% | Jun 17, 2026 |
| Den-Mab Llc Ai | 10% owner | 4,876,344 | 10.44% | May 14, 2026 |
| Len Blavatnik | 10% owner | – | – | May 14, 2026 |
| Access Industries Management, Llc | 10% owner | – | – | May 14, 2026 |
| Industries Holdings LLC Access | 10% owner | – | – | May 14, 2026 |
| Biotechnology LLC AI | 10% owner | – | – | May 14, 2026 |
| Holdings A/S Novo | 10% owner | 4,180,550 | 8.95% | May 6, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. 10% owner | Jun 16, 2026 | Buy | +61,523 | $24.98 | $1.54M | 6,444,637 |
| Ra Capital Management, L.P. 10% owner | Jun 15, 2026 | Buy | +6,146 | $24.89 | $152.97K | 6,383,114 |
| Ra Capital Management, L.P. 10% owner | May 20, 2026 | Buy | +996 | $24.94 | $24.84K | 6,376,968 |
| Ra Capital Management, L.P. 10% owner | May 19, 2026 | Buy | +3,802 | $24.97 | $94.94K | 6,375,972 |
| Peter Kolchinsky 10% owner | May 12, 2026 | Buy | +6,387 | $24.90 | $159.04K | 6,372,170 |
| Capital Healthcare Fund LP RA 10% owner | May 11, 2026 | Buy | +14,149 | $24.47 | $346.23K | 6,340,063 |
| Capital Healthcare Fund LP RA 10% owner | May 11, 2026 | Buy | +25,720 | $25.00 | $643.00K | 6,365,783 |
| Capital Healthcare Fund LP RA 10% owner | May 8, 2026 | Buy | +1,483 | $24.98 | $37.05K | 6,325,914 |
| Capital Healthcare Fund LP RA 10% owner | May 7, 2026 | Buy | +7,921 | $24.34 | $192.80K | 6,322,446 |
| Capital Healthcare Fund LP RA 10% owner | May 7, 2026 | Buy | +1,985 | $24.95 | $49.53K | 6,324,431 |
| Rajeev M. Shah Director, 10% owner | May 6, 2026 | Buy | +14,611 | $23.77 | $347.30K | 6,261,118 |
| Rajeev M. Shah Director, 10% owner | May 6, 2026 | Buy | +53,407 | $24.83 | $1.33M | 6,314,525 |
| Rajeev M. Shah Director, 10% owner | May 5, 2026 | Buy | +87,143 | $24.59 | $2.14M | 6,236,239 |
| Rajeev M. Shah Director, 10% owner | May 5, 2026 | Buy | +10,268 | $25.00 | $256.70K | 6,246,507 |
| Rajeev M. Shah Director, 10% owner | May 4, 2026 | Conversion | +1,009,052 | – | – | 1,009,052 |
| Rajeev M. Shah Director, 10% owner | May 4, 2026 | Conversion | +221,188 | – | – | 221,188 |
| Rajeev M. Shah Director, 10% owner | May 4, 2026 | Buy | +2,541,250 | $18.00 | $45.74M | 6,149,096 |
| Rajeev M. Shah Director, 10% owner | May 4, 2026 | Buy | +133,750 | $18.00 | $2.41M | 354,938 |
| Rajeev M. Shah Director, 10% owner | May 4, 2026 | Conversion | +3,607,846 | – | – | 3,607,846 |
| Holdings A/S Novo 10% owner | May 4, 2026 | Conversion | +4,180,550 | – | – | 4,180,550 |
| John Maraganore Director | May 4, 2026 | Conversion | +17,974 | – | – | 17,974 |
| John Maraganore Director | May 4, 2026 | Conversion | +17,974 | – | – | 35,948 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 6 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Hemab Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 25,800 shares on Aug 27, 2026 over the last 90 days.
See a number that looks wrong?